Methylliberine and theacrine are caffeine-like compounds found in energy drinks and supplements that work by blocking brain receptors to create alertness, but research shows they’re significantly weaker at this than caffeine itself. According to Gram Research analysis, methylliberine also inhibits an enzyme that breaks down many medications, potentially causing drug interactions. Laboratory studies found methylliberine blocked only 52 to 62 percent of adenosine receptors at high concentrations, compared to caffeine’s 95 percent or higher potency, suggesting these compounds produce milder stimulant effects.
Two caffeine-like compounds found in energy drinks and supplements, methylliberine and theacrine, have been studied by researchers using advanced lab techniques to understand how they affect your body. According to Gram Research analysis, these substances work similarly to caffeine by blocking certain brain receptors that make you feel alert, but they’re weaker at doing this job. The study also found that methylliberine could interfere with how your body processes certain medications. While these compounds are already in many products people buy, scientists say we need more human studies to fully understand if they’re safe for everyone.
Key Statistics
A 2026 laboratory study found that methylliberine inhibited the CYP1A2 enzyme with an IC50 value of 9.6 micromoles, potentially slowing how your body processes certain medications.
Research published in 2026 showed that methylliberine and theacrine blocked adenosine receptors at only 52 to 62 percent potency at 100 micromolar concentrations, significantly weaker than caffeine’s 95 percent or higher effectiveness.
A 2026 analysis using computer models predicted that both methylliberine and theacrine could cross the blood-brain barrier like caffeine, suggesting they can reach brain tissue to produce stimulant effects.
Laboratory testing in 2026 found that methylliberine’s metabolite also inhibited the CYP1A2 enzyme, meaning even the breakdown products of this compound could affect how your body processes drugs.
The Quick Take
- What they studied: How two caffeine-like compounds called methylliberine and theacrine affect your body at the cellular level, including how they interact with your brain and how your body breaks them down.
- Who participated: This was a laboratory study using computer models and test tubes, not human volunteers. Researchers tested how these compounds behaved in simulated human systems.
- Key finding: Both methylliberine and theacrine can cross into your brain like caffeine and block adenosine receptors, which creates a stimulant effect, but they’re significantly weaker at this than caffeine itself. Methylliberine also blocks an enzyme that helps your body process certain medications.
- What it means for you: If you consume products with these compounds, they’ll likely give you some of the same alert feeling as caffeine, but probably less intense. The medication interaction finding suggests people taking certain drugs should be cautious, though more human research is needed to confirm real-world risks.
The Research Details
Researchers used three different scientific approaches to study methylliberine and theacrine. First, they used computer models to predict how your body would break down these compounds and whether they could reach your brain. Second, they used computer simulations to estimate how easily these substances could cross the blood-brain barrier, which is like a protective filter around your brain. Third, they conducted laboratory experiments using human cell samples to test how these compounds interact with specific brain receptors and enzymes that affect how your body processes drugs.
This combination of computer predictions and lab experiments is called the new approach methods (NAMs) strategy. It allows scientists to gather safety information without using animals or human volunteers. The researchers compared their findings to caffeine, which is well-studied and familiar to most people, to help put the results in context.
The study focused on several specific interactions: how the compounds bind to adenosine receptors in the brain (which control alertness), how they affect an enzyme called CYP1A2 (which breaks down many drugs), and how they interact with other brain chemicals called phosphodiesterases.
This research approach is important because methylliberine and theacrine are already sold in energy drinks, supplements, and sports products worldwide, yet very little is known about how they actually affect humans. By using multiple testing methods together, researchers can identify potential safety concerns before they cause problems in real people. The findings about enzyme interactions are particularly important because they could explain why some people might have unexpected reactions when combining these supplements with medications.
This study used established scientific methods and compared results across multiple testing approaches, which strengthens confidence in the findings. However, because this is laboratory research and not human studies, the results show what might happen in your body, not what definitely does happen. The researchers were transparent about the limitations of their work. The study was published in a peer-reviewed journal, meaning other scientists reviewed it before publication. The main limitation is that lab results don’t always match real-world effects in living people.
What the Results Show
Both methylliberine and theacrine were predicted by computer models to be broken down in your body through a process called desmethylation, similar to how caffeine is metabolized. This means your liver processes these compounds in predictable ways. Both compounds also appeared capable of crossing the blood-brain barrier, suggesting they can reach the parts of your brain that control alertness and focus.
When tested in laboratory cells, both methylliberine and theacrine blocked adenosine receptors in the brain, specifically the A2A receptor. This blocking action is what creates the stimulant effect that makes you feel more alert. However, their potency was notably weaker than caffeine and other related compounds. At a concentration of 100 micromoles, methylliberine and theacrine only blocked 52 to 62 percent of these receptors, compared to caffeine which blocked 95 percent or more at much lower concentrations.
Methylliberine showed a particularly important finding: it inhibited an enzyme called CYP1A2 with an IC50 value of 9.6 micromoles. This enzyme is responsible for breaking down many common medications and other substances in your body. When an enzyme is inhibited, it works more slowly, which could cause medications to stay in your system longer than intended. This finding matched what has been observed in clinical studies with people.
The study also found that methylliberine’s metabolite, a compound created when your body breaks down methylliberine, also inhibited the CYP1A2 enzyme, though less potently than the original compound. This suggests that even after your body starts processing methylliberine, the resulting breakdown products could still affect how you metabolize drugs. Theacrine did not show significant CYP1A2 inhibition, making it different from methylliberine in this important way. Neither compound showed strong effects on phosphodiesterase enzymes, which are involved in various body functions and are targets of some medications.
This research builds on earlier observations that methylliberine and theacrine exist in nature and are used in traditional beverages and modern supplements. The study confirms that these compounds behave similarly to caffeine in some ways, particularly in how they reach the brain and create stimulant effects. However, the finding that methylliberine inhibits drug-metabolizing enzymes is new and important information that wasn’t well-documented before. The weaker potency at adenosine receptors compared to caffeine explains why people might need higher doses of products containing these compounds to feel the same effects.
The biggest limitation is that this research was conducted in laboratory settings using computer models and cell cultures, not in living humans. What happens in a test tube doesn’t always match what happens in a whole body with complex systems interacting. The study didn’t test actual human volunteers, so we don’t know the real-world doses people are exposed to or how their bodies actually respond. The research also didn’t examine long-term effects or how these compounds might affect different groups of people, such as children, pregnant women, or people with certain health conditions. Additionally, the study focused on isolated interactions and didn’t examine how methylliberine and theacrine might interact with each other or with other substances people consume.
The Bottom Line
Based on this research, people taking medications that are processed by the CYP1A2 enzyme should be cautious about consuming products containing methylliberine, particularly in high amounts. This includes some blood pressure medications, certain antidepressants, and other drugs. If you take medications regularly, discuss any new supplements with your doctor before using them. For general consumers seeking a stimulant effect, methylliberine and theacrine appear to work like caffeine but with weaker effects, so expect less intense alertness compared to coffee or traditional energy drinks. These recommendations have moderate confidence because they’re based on laboratory findings that need human confirmation.
People taking medications processed by CYP1A2 should pay special attention to this research, as should anyone considering using supplements containing methylliberine. Healthcare providers should be aware of these potential interactions when counseling patients. Manufacturers of products containing these compounds should consider these findings when labeling and marketing their products. Healthy adults without medication interactions may be less concerned, though more research is still needed. Pregnant women, nursing mothers, and children should avoid these compounds until human safety studies are completed.
If you were to use a product containing methylliberine or theacrine, you would likely notice any stimulant effects within 30 to 60 minutes, similar to caffeine. However, the potential medication interactions could develop over days or weeks of regular use, as the enzyme inhibition accumulates. Long-term safety effects remain unknown and would require years of human studies to determine.
Frequently Asked Questions
Is methylliberine safe to take with my medications?
Methylliberine may slow how your body processes certain medications by inhibiting the CYP1A2 enzyme, potentially causing unexpected side effects or reduced medication effectiveness. Talk to your doctor or pharmacist before using products containing methylliberine, especially if you take blood pressure medications or antidepressants.
How does theacrine compare to caffeine for energy?
Theacrine works similarly to caffeine by blocking brain receptors that control alertness, but laboratory studies show it’s significantly weaker, blocking only 52 to 62 percent of adenosine receptors compared to caffeine’s 95 percent or higher. You’d likely need higher doses to feel the same energy boost.
Can methylliberine and theacrine cross into my brain?
Computer models predict that both methylliberine and theacrine can cross the blood-brain barrier like caffeine, allowing them to reach brain tissue and produce stimulant effects. However, this prediction hasn’t been confirmed in human studies yet.
Are products with methylliberine and theacrine regulated by the FDA?
These compounds are sold as dietary supplements, which have less strict FDA oversight than medications. The research shows these substances can interact with drug-metabolizing enzymes, highlighting the need for better safety monitoring and labeling of products containing them.
What does this research mean for energy drink safety?
This laboratory study identifies potential safety concerns with methylliberine and theacrine, particularly regarding medication interactions, but doesn’t prove these problems occur in real people. More human studies are needed to determine actual safety risks and appropriate dosing guidelines for consumers.
Want to Apply This Research?
- Track daily intake of products containing methylliberine or theacrine by brand name and serving size, noting the time consumed and any effects like increased alertness, jitteriness, or sleep disruption. Record any medications taken and note if you experience unexpected side effects or changes in medication effectiveness.
- If using an app to monitor supplement intake, set reminders to review your medication list and discuss any new supplements with your healthcare provider before adding them. Create a log comparing how you feel after consuming products with these compounds versus caffeine to understand your personal response.
- Maintain a weekly summary of supplement use, energy levels, sleep quality, and any medication side effects. If you take medications, schedule monthly check-ins with your doctor to discuss supplement use and watch for signs of drug interactions such as unexpected medication side effects or reduced effectiveness.
This article summarizes laboratory research on methylliberine and theacrine and is not medical advice. These findings are based on test-tube and computer studies, not human trials, so real-world effects may differ. If you take medications or have health conditions, consult your doctor or pharmacist before using products containing methylliberine or theacrine. Do not stop taking prescribed medications based on this information. The FDA does not strictly regulate dietary supplements, so product quality and safety vary. Pregnant women, nursing mothers, and children should avoid these compounds until human safety studies are completed.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.